Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turkey Company Roundup: Roche Case Reopens, Sanofi Starts Exports

This article was originally published in PharmAsia News

Executive Summary

The Supreme Court in Turkey has cancelled a statute of limitations decision in a Roche legal case, with some ex-managers and bureaucrats to be retried. Meanwhile, Sanofi Turkey has become the first pharmaceutical company to export antibiotics to Japan from a production site in Turkey, the AIFD has elected a chairman, and Lilly has made new appointments.

You may also be interested in...



Pricing Concerns Delaying Sanofi’s Turkey Insulin Investment?

Despite the political turmoil, Sanofi appears keen to invest in the local manufacturing of an insulin product in Turkey if the government “opens the way”, but is holding off over pricing worries.

Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles

The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems  ̶  and the solutions  ̶  to Medtech Insight.

A Bright Moment At Last In Turkish Medtech Debt Payments Saga

Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC088707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel